Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
Julie Delyon(Inserm), Caroline Robert(Institut Gustave Roussy), Nathalie Chaput(Institut Gustave Roussy), D. Lefeuvre, Céu Mateus(University Dermatology), Séverine Le Roy(Université Paris-Saclay), Alexander M.M. Eggermont(University Medical Center Utrecht), Laurence Zitvogel(Institut Gustave Roussy), Émilie Routier(Université Paris-Saclay), Émilie Lanoy(Université Paris-Sud)
Cited by 314
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k